- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study
- Japan Phase 3 results strengthen CARTISTEM's® global commercial prospects, with Japan biologics license application (BLA) scheduled for 2H 2026
SEOUL, South Korea and TOKYO, May 14, 2026 /PRNewswire/ -- MEDIPOST has met all primary and secondary efficacy endpoints in the Japan Phase 3 clinical trial of CARTISTEM®, demonstrating clinical improvements in pain and function as well as cartilage regeneration. Based on the results, MEDIPOST is expected to accelerate preparations for its biologics license application (BLA) filing in Japan later this year.
MEDIPOST (CEO Wonil Oh), a global leader in stem cell biotherapeutics, announced today that the Japan Phase 3 clinical trial of its knee osteoarthritis treatment CARTISTEM® achieved statistical significance across all primary and secondary efficacy endpoints. The results showed improvements not only in symptoms, including pain and function, but also in cartilage regeneration, marking an important milestone in the company's global market expansion strategy.
The trial was a randomized, controlled study conducted at 13 sites(hospitals) in Japan enrolling 130 participants. Subjects were randomized into the CARTISTEM® treatment group, comprising 59 patients, and the hyaluronic acid (HA) control group, comprising 61 patients. Efficacy and safety were evaluated over a 52-week follow-up period.
The trial adopted a randomized design to evenly distribute baseline demographic and clinical characteristics between the two groups, enhancing the objectivity of the results. The mean age of patients was 61.3 years in the CARTISTEM® treatment group and 62.2 years in the control group. Other baseline clinical parameters, including Kellgren-Lawrence (K&L) Grade for osteoarthritis severity, International Cartilage Repair Society (ICRS) Grade for cartilage defect severity, and baseline pain scores, were well balanced, with no statistically significant difference between the two groups, ensuring the reliability of the clinical findings.
CARTISTEM® demonstrated statistically significant improvements over the active control group on both co-primary endpoints: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a knee pain and function index, and improvements in International Cartilage Repair Society (ICRS) grade against control(WOMAC p <0.0001 and ICRS p =0.0002).
Statistically significant improvements were also confirmed across all secondary endpoints. Notable improvements were observed in key indicators including the Visual Analog Scale (VAS), which measures pain intensity, as well as the International Knee Documentation Committee (IKDC) and Knee Injury and Osteoarthritis Outcome Score (KOOS), both of which assess knee function. The p-values for VAS, IKDC, and KOOS were all less than <0.0001. Marked improvements were likewise demonstrated in the WOMAC subscale indicators for pain, function, and stiffness (p <0.0001).
CARTISTEM® maintained an excellent safety profile throughout the trial. All reported serious adverse events (SAEs) were assessed as having no causal relationship to CARTISTEM®.
In particular, results for WOMAC (p-value <0.0001) and the 100 mm VAS (p-value <0.0001), which are the identical primary endpoints utilized in the ongoing U.S. Phase 3 trial, showed statistically significant superiority over the active control. These findings serve as positive indicators for MEDIPOST's U.S. clinical development efforts.
Antonio Lee, Global President of MEDIPOST and CEO of MEDIPOST K.K. (Japan) & Co-CEO of MEDIPOST Inc. (U.S.), stated, "The Japan Phase 3 results have reaffirmed CARTISTEM®'s strong efficacy and safety profile." He added, "The consistency observed across all co-primary and secondary endpoints demonstrates significant clinical implications. In particular, the cartilage regeneration effect of CARTISTEM® that was demonstrated in the Korea Phase 3 trial has now been reconfirmed in the Japan Phase 3 study. We believe these results will provide a solid foundation for CARTISTEM®'s global market entry as a Disease-Modifying OA Drug (DMOAD)."
Meanwhile, MEDIPOST plans to accelerate its entry into the Japanese market by submitting a marketing authorization application later this year, targeting regulatory approval by end of 2027. The company has already established a commercial partnership through an exclusive distribution agreement with Teikoku Seiyaku Co., Ltd.. Following regulatory approval and commercial launch, MEDIPOST expects to generate tangible business outcomes in Japan through finished product supply revenues and sales-based milestone payments.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
|
DUBAI, UAE, May 14, 2026 /PRNewswire/ -- Robo.ai Inc. (Nasdaq: AIIO), announced today that its wholly-owned AI data processing and compression technology subsidiary, Neurovia AI, has officially released its core technology platform, NeuroStream™. Designed for the machine economy era, the platform utilizes a bitmap vectorization algorithm to provide high-fidelity, low-bandwidth, and low-power infrastructure support for the massive visual data generated by physical artificial intelligence. Mansoor Ali Khan, Chief Technology Officer of Neurovia AI, detailed the platform's technical architecture and application cases.
To demonstrate the practical performance of NeuroStream™, Neurovia AI has published comparative case studies on its official website (https://www.neuroviaai.ae/). According to internal testing, a 5.5GB 4K 60fps original video processed through NeuroStream™ can be compressed to a file size of 278MB, reducing storage space usage by approximately 95%.
These tests indicate that NeuroStream™ significantly reduces file size while fully retaining core visual information such as the original video's resolution and frame rate. This visually lossless characteristic ensures that the substantially compressed data continues to provide a clean and complete data source for subsequent machine vision and AI computations. This capability meets the strict data authenticity requirements of industrial, sovereign, and specific legal application scenarios, while also generating clear economic benefits for enterprises in terms of energy consumption, storage space, and processing latency.
Chief Technology Officer Mansoor Ali Khan noted that global unit data storage prices have increased approximately fourfold since 2026. According to industry estimates, every terabyte of data storage saved generates a direct economic benefit of $1,000 to $1,500 annually for an AI customer, in addition to indirect benefits related to transmission efficiency, energy consumption, data integrity, and security.
Through AI-native compression, intelligent visual optimization, and edge computing adaptation, NeuroStream™ converts traditional bitmap logic into a vectorized mathematical expression. This approach lowers transmission and storage costs while precisely preserving the critical visual information necessary for AI computation, offering an effective solution to rising storage expenses.
The platform provides native format compatibility with zero decompression usage costs, as processed images and videos maintain their original formats and can be directly accessed by systems without specific decompression software. This full compatibility with existing conventional video workflows substantially reduces system integration and friction costs for enterprises.
Furthermore, NeuroStream™ optimizes data quality and enhances machine vision recognition accuracy by intelligently improving the data signal-to-noise ratio during processing. This process aids in increasing the computational efficiency of AI algorithms and ensures that machines maintain high recognition accuracy on the compressed data.
The platform features an architecture adapted for low-computing edge deployment, enabling standard commercial computing devices to efficiently process hundreds of terabytes of data. This characteristic makes the platform suitable for deployment on edge sensors, drones, and mobile terminal nodes with limited computing resources. Additionally, the product ensures data security and privacy protection through lossless offline operation, allowing it to function independently in disconnected environments to meet the data compliance requirements of highly sensitive industries such as aerospace, medical imaging, and energy.
Moving forward, Neurovia plans to progressively introduce the NeuroStream™ platform to core application scenarios including autonomous driving, robotics, smart cities, industrial AI, and global intelligent networks. As the deployment scale of global edge computing nodes expands, NeuroStream™ is expected to effectively reduce network bandwidth pressure and overall energy consumption in data centers. This will enable global machine vision networks to become more efficient, real-time, and intelligent, providing solid infrastructure support for the large-scale commercial deployment of the machine economy.
About Neurovia AI Limited
Neurovia AI (www.neuroviaai.ae) provides AI data processing and visual infrastructure through its NeuroStream™ platform. Dedicated to transitioning visual data from human viewing to machine understanding, the company utilizes AI-native compression and edge computing to address data bottlenecks in Physical AI. Its technology serves autonomous driving, smart cities, and intelligent manufacturing, providing a foundational layer for global machine perception and collaboration.
About Robo.ai Inc.
Robo.ai Inc. (NASDAQ: AIIO) is a technology company dedicated to building an artificial intelligence machine economy platform. Its mission is to integrate smart terminals through AI software, intelligent hardware, and smart assets to construct a unified artificial intelligence operating system and a blockchain-empowered ecosystem to pioneer an intelligent future.
Safe Harbor Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations; for further details, please refer to the documents the company has filed with the U.S. Securities and Exchange Commission.
Media Contacts
Neurovia AI Corporate Communications
Email: info@neuroviaai.ae
Website: www.neuroviaai.ae
Robo.ai Inc. Corporate Communications
Email: pr@roboai.io
Website: www.roboai.io
DUBAI, UAE, May 14, 2026 /PRNewswire/ -- Robo.ai Inc. (Nasdaq: AIIO), announced today that its wholly-owned AI data processing and compression technology subsidiary, Neurovia AI, has officially released its core technology platform, NeuroStream™. Designed for the machine economy era, the platform utilizes a bitmap vectorization algorithm to provide high-fidelity, low-bandwidth, and low-power infrastructure support for the massive visual data generated by physical artificial intelligence. Mansoor Ali Khan, Chief Technology Officer of Neurovia AI, detailed the platform's technical architecture and application cases.
To demonstrate the practical performance of NeuroStream™, Neurovia AI has published comparative case studies on its official website (https://www.neuroviaai.ae/). According to internal testing, a 5.5GB 4K 60fps original video processed through NeuroStream™ can be compressed to a file size of 278MB, reducing storage space usage by approximately 95%.
These tests indicate that NeuroStream™ significantly reduces file size while fully retaining core visual information such as the original video's resolution and frame rate. This visually lossless characteristic ensures that the substantially compressed data continues to provide a clean and complete data source for subsequent machine vision and AI computations. This capability meets the strict data authenticity requirements of industrial, sovereign, and specific legal application scenarios, while also generating clear economic benefits for enterprises in terms of energy consumption, storage space, and processing latency.
Chief Technology Officer Mansoor Ali Khan noted that global unit data storage prices have increased approximately fourfold since 2026. According to industry estimates, every terabyte of data storage saved generates a direct economic benefit of $1,000 to $1,500 annually for an AI customer, in addition to indirect benefits related to transmission efficiency, energy consumption, data integrity, and security.
Through AI-native compression, intelligent visual optimization, and edge computing adaptation, NeuroStream™ converts traditional bitmap logic into a vectorized mathematical expression. This approach lowers transmission and storage costs while precisely preserving the critical visual information necessary for AI computation, offering an effective solution to rising storage expenses.
The platform provides native format compatibility with zero decompression usage costs, as processed images and videos maintain their original formats and can be directly accessed by systems without specific decompression software. This full compatibility with existing conventional video workflows substantially reduces system integration and friction costs for enterprises.
Furthermore, NeuroStream™ optimizes data quality and enhances machine vision recognition accuracy by intelligently improving the data signal-to-noise ratio during processing. This process aids in increasing the computational efficiency of AI algorithms and ensures that machines maintain high recognition accuracy on the compressed data.
The platform features an architecture adapted for low-computing edge deployment, enabling standard commercial computing devices to efficiently process hundreds of terabytes of data. This characteristic makes the platform suitable for deployment on edge sensors, drones, and mobile terminal nodes with limited computing resources. Additionally, the product ensures data security and privacy protection through lossless offline operation, allowing it to function independently in disconnected environments to meet the data compliance requirements of highly sensitive industries such as aerospace, medical imaging, and energy.
Moving forward, Neurovia plans to progressively introduce the NeuroStream™ platform to core application scenarios including autonomous driving, robotics, smart cities, industrial AI, and global intelligent networks. As the deployment scale of global edge computing nodes expands, NeuroStream™ is expected to effectively reduce network bandwidth pressure and overall energy consumption in data centers. This will enable global machine vision networks to become more efficient, real-time, and intelligent, providing solid infrastructure support for the large-scale commercial deployment of the machine economy.
About Neurovia AI Limited
Neurovia AI (www.neuroviaai.ae) provides AI data processing and visual infrastructure through its NeuroStream™ platform. Dedicated to transitioning visual data from human viewing to machine understanding, the company utilizes AI-native compression and edge computing to address data bottlenecks in Physical AI. Its technology serves autonomous driving, smart cities, and intelligent manufacturing, providing a foundational layer for global machine perception and collaboration.
About Robo.ai Inc.
Robo.ai Inc. (NASDAQ: AIIO) is a technology company dedicated to building an artificial intelligence machine economy platform. Its mission is to integrate smart terminals through AI software, intelligent hardware, and smart assets to construct a unified artificial intelligence operating system and a blockchain-empowered ecosystem to pioneer an intelligent future.
Safe Harbor Statement
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations; for further details, please refer to the documents the company has filed with the U.S. Securities and Exchange Commission.
Media Contacts
Neurovia AI Corporate Communications
Email: info@neuroviaai.ae
Website: www.neuroviaai.ae
Robo.ai Inc. Corporate Communications
Email: pr@roboai.io
Website: www.roboai.io
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Robo.ai Subsidiary Neurovia AI Launches NeuroStream™ Technology Platform to Build Physical AI Visual Data Infrastructure
